



Norman Putzki

Kontakt

Norman Putzki

Bereiche

Neurologie

Publikationen (46)

Pardini M, Putzki N, Tettenborn B, Valmaggia C, Würfel J, Gass A, Kuhle J, Vehoff J, Müller S, Botzkowski D, Yaldizli O (2015). Brain metabolites and retinal nerve fibre layer thickness and their relation to disability in multiple sclerosis: a longitudinal high-field proton magnetic resonance spectroscopy and optical coherence tomography study.

Yaldizli O, Glassl S, Sturm D, Papadopoulou A, Gass A, Tettenborn B, Putzki N. Fatigue and progression of corpus callosum atrophy in multiple sclerosis. *J Neurol* 2011; 258:2199–205.

Tettenborn B, Yildiz M, Putzki N. Vitamin D levels in Swiss multiple sclerosis patients. *Swiss Med Wkly* 2011

Yildiz M, Tettenborn B, Putzki N. Vitamin D levels in Swiss multiple sclerosis patients. *Swiss Med Wkly* 2011; 141:w13192.

Yildiz M, Tettenborn B, Putzki N. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate. *Eur Neurol* 2011; 65:231-2.

Yildiz M, Tettenborn B, Putzki N (2010). Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate.

Yildiz M, Tettenborn B, Putzki N. Natalizumab and beyond. *Eur Neurol* 2010; 64:236–40.

Putzki N, Stich O, Gartzen K, Kastrup O, Tettenborn B, Rauer S. Natalizumab treatment in paediatric multiple sclerosis: a case of induction, de-escalation and escalation. *Eur J Neurol* 2010; 17:e105.

Putzki N, Katsarava Z. Headache in multiple sclerosis. *Curr Pain Headache Rep* 2010; 14:316–20.

Tettenborn B, Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Maschke M, Limmroth V. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. *Eur J Neurol* 2010; 17 (1):31-7.

Putzki N, Baranwal M, Tettenborn B, Limmroth V, Kreuzfelder E. Effects of Natalizumab on Circulating B Cells, T Regulatory Cells and Natural Killer Cells. *Eur Neurol* 2010; 63:311–317.

Yaldizli O, Atefy R, Gass A, Sturm D, Glassl S, Tettenborn B, Putzki N. Corpus callosum index and long-term disability in multiple sclerosis patients. *J Neurol* 2010; 257:1256–64.

Putzki N, Yaldizli O, Bühler R, Schwegler G, Curtius D, Tettenborn B. Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland. *Eur Neurol* 2010; 63:101–106.

Putzki N, Yaldizli O, Tettenborn B, Diener H. Multiple sclerosis associated fatigue during natalizumab treatment. *Journal of the neurological sciences* 2009; 285:109–13.

Yaldizli O, Kumar M, Vago S, Kreuzfelder E, Limmroth V, Putzki N. Fatigue Is Not Associated with Impaired Function of Regulatory T Cells in Untreated Patients with Multiple Sclerosis. *European neurology* 2009; 62:321–326.

Putzki N, Yaldizli O. Fatigue bei MS – CME Fortbildung. Der Neurologe und Psychiater (DNP) 2009; 8
Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. European journal of neurology : the official journal of the European Federation of Neurological Societies 2009
Kägi G, Yaldizli O, Tettenborn B, Putzki N (2009). Spinal Pseudoathetosis in a patient with Multiple Sclerosis. Präsentiert bei: 182th Meeting of the Swiss Neurological Society, Interlaken
Putzki N. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. European journal of neurology : the official journal of the European Federation of Neurological Societies 2009; 16:713-20.
Yaldizli O, Baumberger P, Putzki N. Natalizumab and atypical naevi. Annales de dermatologie et de vénéréologie 2009; 136:450-1.
Putzki N. Natalizumab in the treatment of multiple sclerosis. Therapeutic Adv Neurol 2009; 2:115-128.
Kollia K, Maderwald S, Putzki N, Schlamann M, Theysohn J, Kraff O, Ladd M, Forsting M, Wanke I. First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T. AJNR. American journal of neuroradiology 2009; 30:699-702.
Putzki N. Innovative orale Therapien der schubförmigen MS. Schweizer Zeitschrift für Psychiatrie & Neurologie 2009; 1:32-39.
Putzki N, Kollia K, Woods S, Igwe E, Diener H, Limmroth V. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. European journal of neurology : the official journal of the European Federation of Neurological Societies 2009; 16:424-6.
Tettenborn B, Putzki N, Pfriem A, Limmroth V, Yaldizli O, Diener H, Katsarava Z. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol 2009; 16(2):262-7.
Putzki N, Pfriem A, Limmroth V, Yaldizli O, Tettenborn B, Diener H, Katsarava Z. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. European journal of neurology : the official journal of the European Federation of Neurological Societies 2009; 16:262-7.
Putzki N, Kumar M, Kreuzfelder E, Grosse-Wilde H, Diener H, Limmroth V. Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. A longitudinal ex vivo and in vitro study. European neurology 2009; 61:27-32.
Putzki N, Hartung H. Treatment of Multiple Sclerosis. Bremen: Unimed, 2009. ISBN 978-3-8374-2093-7.
Putzki N, Yaldizli O, Tettenborn B. Fatigue bei therapierten und untherapierten Patienten mit schubförmiger und sekundär progredienter Multipler Sklerose. Aktuelle Neurologie 2008; 9
Tettenborn B, Putzki N, Yaldizli O. Fatigue bei therapierten und untherapierten Patienten mit schubförmiger und sekundär progredienter Multipler Sklerose. Aktuelle Neurologie 2008; 9:9.

Obermann M, Diener H, Gizewski E, Vollmer-Haase J, Putzki N, Buhl A, Tumczak F, Lachenmayer M, Konczak J, de Greiff A, Yaldizli O, Maschke M. Increased basal-ganglia activation performing a non-dystonia-related task in focal dystonia. *European journal of neurology : the official journal of the European Federation of Neurological Societies* 2008; 15:831-8.

Putzki N, Graf K, Stude P, Diener H, Maschke M. Habituation of the auditory startle response in cervical dystonia and Parkinson's disease. *European neurology* 2008; 59:172-8.

Putzki N, Katsarava Z, Vago S, Diener H, Limmroth V. Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients. *European neurology* 2008; 59:136-42.

Gartzen K, Limmroth V, Putzki N. Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. *European journal of neurology : the official journal of the European Federation of Neurological Societies* 2007; 14:e12-3.

Putzki N, Limmroth V. QUASIMS: eine deutschlandweite Beobachtungsstudie der Interferon-Beta-Präparate zur Therapie der schubförmigen multiplen Sklerose. *Aktuelle Neurologie* 2007; 01

Limmroth V, Wernsdörfer C, Kalski G, Putzki N, Hasford J, Brosig A, Meier U, Viehöver A, Obhof W, Elias W, Haller P, Japp G, Koehler J, Zetl U, Malessa R, QUASIMS Study Group. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. *Journal of neurology* 2007; 254:67-77.

Putzki N. 1000 Fragen zur Facharztprüfung Neurologie (1000 questions to prepare medical board examination in neurology). Stuttgart: Thieme, 2007.

Kumar M, Kreuzfelder E, Hardt C, Mueller N, Knop D, Lindemann M, Remus R, Limmroth V, Putzki N, Grosse-Wilde H. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. *Journal of neuroimmunology* 2006; 180:178-84.

Putzki N, Knipp S, Ramczykowski T, Vago S, Germing U, Diener H, Limmroth V. Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2006; 12:363-6.

Putzki N, Stude P, Konczak J, Graf K, Diener H, Maschke M. Kinesthesia is impaired in focal dystonia. *Movement disorders : official journal of the Movement Disorder Society* 2006; 21:754-60.

Putzki N, Nirkko A, Diener H. Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome?. *Cephalalgia : an international journal of headache* 2005; 25:395-7.

Limmroth V, Putzki N. High-dose, frequently administered interferon beta. *Journal of the neurological sciences* 2005; 231:95-6; author reply 97-9.

Putzki N. Guidelines of the German Neurological Society for diagnostic and treatment of neurological diseases - DGN Guidelines. Stuttgart: Thieme, 2004.

Putzki N. Langzeittherapie der MS mit Interferon-beta 1a i. m. (Long term therapy of MS with IFN-beta 1a i.m.). ME, 2004.

Kowacs F, Giffin N, Putzki N, Goadsby P, Kaube H. Nociceptive-specific blink reflex and glyceryl trinitrate infusion in healthy volunteers. *European journal of neurology : the official journal of the European Federation of Neurological Societies* 2003; 10:295-9.

Putzki N, Maschke M, Drepper J, Diener H, Timmann D. Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson's disease. *Journal of neurology* 2002; 249:824-8.

Projekte (9)

Tenere: A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis

Klinische Forschung - 03.05.2010 - 30.06.2011

Abgeschlossen

Fatigue in Multiple Sclerosis now and then: a cross-sectional study

Klinische Forschung - 30.11.2009 - 30.04.2009

Abgeschlossen

Selective S1P1 receptor agonist in Patients with Relapsing-Remitting Multiple Sclerosis

Klinische Forschung - 01.11.2009 - 01.11.2010

Abgeschlossen

Subkutane Mehrfachdosierungen von LY2127399, einem menschlichen Anti-BAFF-Antikörper, bei Patienten mit schubförmig remittierender multipler Sklerose

Klinische Forschung - 01.11.2009 - 01.05.2011

Abgebrochen

The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Klinische Forschung - 24.09.2009 - 24.09.2011

Automatisch geschlossen

A prospective MR spectroscopy study to investigate axonal loss in different stages of multiple sclerosis

Klinische Forschung - 24.07.2009 - 24.09.2011

Abgeschlossen

Corpus Callosum Index and long-term disability in multiple sclerosis patients

Klinische Forschung - 30.01.2009 - 30.01.2009

Abgeschlossen

A retrospective, Swiss multi-center study to investigate the efficacy of natalizumab in second line therapy

Klinische Forschung - 02.10.2008 - 02.10.2009

Abgeschlossen

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of dimethyl fumarate (BG00012) in Subjects with Relapsing-Remitting Multiple Sclerosis

Klinische Forschung - 01.10.2008 - 01.12.2010

Abgeschlossen

